Updated version of this database is available at ThpDB2

Detailed description page of THPdb

This page displays user query in tabular form.

1431 details
Primary information
ThPP IDTh1073
Therapeutic Peptide/Protein NameAlemtuzumab
SequenceHeavy Chain 1: QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMN view full sequnce in fasta
Functional ClassificationIIa
Molecular Weight145453.8
Chemical FormulaC6468H10066N1732O2005S40
Isoelectric Point8.76
Hydrophobicity-0.431
Melting Point (℃)61 (FAB f
Half Life288 hrs
DescriptionHumanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein,CD52. The Campath-1H antibody is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Campath is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin.
Indication/DiseaseAlemtuzumab (Campath) is a monoclonal antibody therapy used for treatment of B-cell chronic lymphocytic leukemia.
PharmacodynamicsCampath is used to treat leukemia by exploiting antibody mediated lysis of CD52 presenting cells. The CD52 antigen is a cell surface protein found on essentially all B and T lymphocytes, a majority of monocytes, macrophages and most granulocytes. The CD52 antigen is not present on erythrocytes or hematopoetic stem cells. In leukemia there is an excess of B and T cells, so Campath permits selective reduction of lymphocyte populations.
Mechanism of ActionCampath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells.
ToxicityN.A.
MetabolismMost likely removed by opsonization via the reticuloendothelial system when bound to B or T lymphocytes
AbsorptionN.A.
Volume of Distribution0.18 L/kg
ClearanceN.A.
CategoriesN.A.
Patents NumberCA1339198
Date of Issue06/08/01
Date of Expiry06/08/18
Drug InteractionTrastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
TargetN.A.
Information of corresponding available drug in the market
Brand NameCAMPATH
CompanyGenzyme Corporation
Brand DiscriptionCampath (alemtuzumab) is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) directed against the 21-28 kD cell surface glycoprotein, CD52. Campath-1H is an IgG1 kappa antibody with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). The Campath-1H antibody has an approximate molecular weight of 150 kD. Campath is produced in mammalian cell (Chinese hamster ovary) 
Prescribed forCampath is a CD52-directed cytolytic antibody indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL)
Chemical NameN.A.
FormulationEach single use vial of Campath contains 30 mg alemtuzumab, 8.0 mg sodium chloride, 1.44 mg dibasic sodium phosphate, 0.2 mg potassium chloride, 0.2 mg monobasic potassium phosphate, 0.1 mg polysorbate 80, and 0.0187 mg disodium edetate dihydrate. No preservatives are added.
Physcial AppearnceCampath is a sterile, clear, colorless, isotonic solution (pH 6.8-7.4) for injection.
Route of AdministrationIntravenous infusion
Recommended DosageAdminister as an IV infusion over 2 hours, Escalate to recommended dose of 30 mg/day three times per week for 12 weeks, Premedicate with oral antihistamine and acetaminophen prior to dosing
ContraindicationNone
Side EffectsMost common adverse reactions (>=10%): cytopenias, infusion reactions, cytomegalovirus (CMV) and other infections, nausea, emesis, diarrhea, and insomnia.
Useful Linkhttp://www.rxlist.com/campath-drug.htm
PubMed ID27645339, 26384035, 26253589, 25887773, 25846320, 24090587, 19967103, 16810345, 16179960, 18588450, 12130484, 17051245, 9593475
3-D StructureTh1073 (View) or (Download)